Picture Kentro Design Corporate and Web Design for Start Ups 650x80px

Document › Details

CureVac N.V.. (12/23/20). Web Site: Leadership – Executive Board, Supervisory Board and Scientific Advisory Board. [https://www.curevac.com, 12/23/20]

	Organisation	CureVac N.V. (Nasdaq: CVAC)
	Organisation 2	BIO Deutschland e. V.
	Product	mRNA technology
	Product 2	mRNA-based vaccine
	Person	Haas, Franz-Werner (CureVac 202008– CEO joined 201206 as COO before Sygnis + Lion BIoscience)
	Person 2	Bronsema, Viola (BIO Deutschland 200905 Managing Director + CureVac 202008– Supervisory Board Member)

Record changed: 2021-01-13

Picture [iito] Plain Stupid Simple 650x80px

More documents for CureVac N.V. (Nasdaq: CVAC)

[1] CureVac N.V.. (2/12/21). "Press Release: CureVac Initiates Rolling Submission with European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV". Tübingen & Boston, MA....
[2] GlaxoSmithKline plc. (2/3/21). "Press Release: GSK and CureVac to Develop Next Generation mRNA COVID-19 Vaccines". London, Tübingen & Boston, MA....
[3] CureVac N.V.. (1/28/21). "Press Release: CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares". Tübingen & Boston, MA....
[4] CureVac N.V.. (1/25/21). "Press Release: CureVac Announces Proposed Public Offering of Common Shares". Tübingen & Boston, MA....
[5] CureVac N.V.. (1/7/21). "Press Release: CureVac and Bayer Join Forces on COVID-19 Vaccine Candidate CVnCoV". Berlin, Tübingen & Boston; MA....
[6] CureVac N.V.. (12/9/20). "Press Release: CureVac and Fareva Sign Agreement for Fill & Finish Manufacturing of Curevac’s COVID-19 Vaccine Candidate, CVnCoV". Tübingen & Boston, MA....
[7] CureVac N.V.. (12/4/20). "Press Release: CureVac Appoints Antony Blanc as Chief Business Officer and Chief Commercial Officer". Tübingen & Boston, MA....
[8] Kaleido Biosciences, Inc.. (10/1/20). "Press Release: Kaleido Biosciences Appoints Daniel Menichella as President and Chief Executive Officer". Lexington, MA....
[9] CureVac N.V.. (9/29/20). "Press Release: CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate. Study Conducted in Peru and Panama". Tübingen & Boston, MA....
[10] CureVac B.V.. (8/18/20). "Press Release: CureVac Announces Closing of Initial Public Offering". Tübingen & Boston, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]